1 / 3

Dystrophin (DMD) - Pipeline Review, H1- Market Report 2017

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.<br>

InsightReports
Download Presentation

Dystrophin (DMD) - Pipeline Review, H1- Market Report 2017

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dystrophin (DMD) - Pipeline Review, H1- Market Size And Share Report 2017 “The report reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or According to the recently published report 'Dystrophin (DMD) - Pipeline Review, H1 2017' Dystrophin (DMD) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma Browse Full Research Report @: http://www.radiantinsights.com/research/dystrophin- dmd-pipeline-review-h1-2017 The report 'Dystrophin (DMD) - Pipeline Review, H1 2017' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 8 and 10 Follow Us:

  2. respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy and Muscular Dystrophy. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Request A Sample Copy Of This Report at: http://www.radiantinsights.com/research/dystrophin-dmd-pipeline-review-h1- 2017/request-sample Scope The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD) The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics Reasons to Buy Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Dystrophin (DMD) Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics Follow Us:

  3. Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare About Radiant Insights,Inc: Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036, San Francisco, CA 94105, United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Web: http://www.radiantinsights.com/ Visit Our Blog: https://radiantinsightsincblog.wordpress.com/ Follow Us:

More Related